



9<sup>th</sup> January 2017

To,

(a) BSE Limited  
Listing Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001

(b) National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E)  
Mumbai-400 051

(c) Societe De La Bourse De Luxemberg  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

Dear Sirs,

This is to inform you that the Board of Directors of the Company through a circular resolution on 9<sup>th</sup> January 2017 has appointed Mr. Peter Lankau as an Additional Director of the Company with effect from 10<sup>th</sup> January 2017 to hold office as an Independent Director of the Company.

Mr. Peter Lankau has graduated with Bachelors of Science in Biology from the State University of New York at Albany, USA. He has over 30 years of management experience in developing and commercializing pharmaceutical products.

He is currently a principal of Lankau Consulting LLC. He was previously Executive Chairman of the Board for Nautilus Neurosciences, Inc., Chairman & CEO of Logical Therapeutics, Inc. and President & CEO of Endo Pharmaceuticals, Inc. Prior to Endo Pharmaceuticals Inc., he was VP, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi).

He currently serves on the Board of Directors of ANI Pharmaceuticals, Inc. and Phosphagenics Limited and also on the Board of Advisors of Orchard Venture Partners, a life sciences venture capital firm.

He is not related to any Director of the Company.

This is for your information and records.

Thank You

Yours faithfully,  
For Cipla Limited

Mital Sanghvi  
Company Secretary